Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study
Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study
*DJ Roche: Phase 3 Study Shows Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning
(MORE TO FOLLOW) Dow Jones Newswires
March 22, 2021 02:03 ET (06:03 GMT)
*DJ Roche: Study Met Its Primary Endpoint of Disease-Free Survival at Interim Analysis
(MORE TO FOLLOW) Dow Jones Newswires
March 22, 2021 02:05 ET (06:05 GMT)
*DJ Roche: Tecentriq Showed Statistically Significant Improvement in Disease-Free Survival as Adjuvant Therapy Following Surgery and Chemotherapy
(END) Dow Jones Newswires
March 22, 2021 02:05 ET (06:05 GMT)
DJ Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study
By Cecilia Butini
Roche Holding AG said Monday that a Phase 3 study on its monoclonal antibody drug Tecentriq met the primary endpoint of providing disease-free survival to lung cancer patients.
The Swiss pharmaceutical major said the drug showed a statistically significant improvement in disease-free survival for patients suffering non-small-cell lung cancer after surgery and chemotherapy.
Tecentriq is already approved for five indications for different types of lung cancer in markets around the world, Roche said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 22, 2021 02:15 ET (06:15 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
*DJ Roche: Phase 3 Study Shows Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning
*DJ羅氏：第三階段研究顯示，Tecentriq幫助早期肺癌患者延長了壽命，而不會復發
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 22, 2021 02:03 ET (06:03 GMT)
2021年3月22日東部時間02：03(格林威治時間06：03)
*DJ Roche: Study Met Its Primary Endpoint of Disease-Free Survival at Interim Analysis
*DJ羅氏：研究在中期分析中遇到其無病生存的主要終點
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 22, 2021 02:05 ET (06:05 GMT)
2021年3月22日東部時間02：05(格林尼治標準時間06：05)
*DJ Roche: Tecentriq Showed Statistically Significant Improvement in Disease-Free Survival as Adjuvant Therapy Following Surgery and Chemotherapy
*DJ羅氏：Tecentriq在手術和化療後作為輔助治療的無病生存方面顯示出統計上的顯著改善
(END) Dow Jones Newswires
(完)道瓊通訊社
March 22, 2021 02:05 ET (06:05 GMT)
2021年3月22日東部時間02：05(格林尼治標準時間06：05)
DJ Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study
DJ羅氏公司的Tecentriq公司在3期肺癌研究中遇到主要終點
By Cecilia Butini
塞西莉亞·布蒂尼(Cecilia Butini)
Roche Holding AG said Monday that a Phase 3 study on its monoclonal antibody drug Tecentriq met the primary endpoint of providing disease-free survival to lung cancer patients.
羅氏控股公司(Roche Holding AG)週一表示，其單克隆抗體藥物Tecentriq的第三階段研究達到了為肺癌患者提供無病生存的主要終點。
The Swiss pharmaceutical major said the drug showed a statistically significant improvement in disease-free survival for patients suffering non-small-cell lung cancer after surgery and chemotherapy.
這位瑞士製藥專業人士表示，該藥物顯示，在手術和化療後，非小細胞肺癌患者的無病生存率在統計上有顯着改善。
Tecentriq is already approved for five indications for different types of lung cancer in markets around the world, Roche said.
羅氏説，Tecentriq已經在世界各地的市場上被批准用於不同類型肺癌的五種適應症。
Write to Cecilia Butini at cecilia.butini@wsj.com
寫信給塞西莉亞·布蒂尼(Cecilia Butini)，電子郵件：cecilia.butini@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
March 22, 2021 02:15 ET (06:15 GMT)
2021年3月22日東部時間02：15(格林尼治標準時間06：15)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧